Contact Information: Contact: Kimberly Brooks 212-827-4378
Patent Partner Todd Lorenz Joins King & Spalding's Intellectual Property Group
| Source: King & Spalding
SAN FRANCISCO, CA--(Marketwire - July 24, 2008) - King & Spalding, a leading international
law firm, announced today that Todd A. Lorenz, a patent lawyer with
significant experience in the biotechnology and pharmaceutical fields, has
joined the firm as a partner in its intellectual property practice group.
Lorenz will be resident in the firm's San Francisco office.
"The addition of Todd reflects our commitment to strategically enhance our
Life Sciences practice with top-tier lateral hires," said Courtland L.
Reichman, head of the firm's intellectual property practice group.
Lorenz joins King & Spalding from Dorsey & Whitney LLP where he was a
partner and served as co-chair of Dorsey's Life Sciences practice. He has
over fifteen years of experience in the acquisition, licensing and
litigation of biotech patents, and represents a number of emerging and
public biotech companies, leading universities, and venture firms in the
fields of immunology, oncology, neurology and molecular biology. He has
worked with leaders in large molecule and cell-based therapeutics,
including antibodies, peptides, stem cells, gene therapy, siRNA, antisense,
vaccines and adjuvants; clinical and research diagnostics, including novel
targets and analytical platforms; and fundamental molecular biology
reagents and procedures.
Lorenz earned a B.S. from Rensselaer Polytechnic Institute, and a J.D. from
Boston University School of Law.
King & Spalding has one of the broadest and deepest benches of lawyers,
scientists and consultants in the United States specializing in the
representation of pharmaceutical, biotechnology and medical technology
companies. More than 125 lawyers and professionals devote all or a
substantial portion of their practices to clients in these industries, with
specialized experience at every stage of the product life cycle -- from
emerging growth company counseling on intellectual property and clinical
trials, through licensing and finance, to FDA approval, manufacturing, and
marketing, and post-approval regulatory, transactional, and litigation
matters. Since the opening of its San Francisco and Silicon Valley offices
earlier this year, the firm has added 24 lawyers and professionals in
California who focus on advising pharmaceutical, biotech, and medical
device companies.
King & Spalding's intellectual property practice group consists of more
than 100 lawyers and patent agents in the firm's offices in Atlanta,
Charlotte, Houston, New York, San Francisco, Silicon Valley, and
Washington, D.C. The group houses a "full service" intellectual property
practice, including significant capabilities in patent litigation and
prosecution, trademark litigation and prosecution, and false advertising.
About King & Spalding
King & Spalding is an international law firm with more than 800 lawyers in
Abu Dhabi, Atlanta, Austin, Charlotte, Dubai, Frankfurt, Houston, London,
New York, Riyadh (affiliated office), San Francisco, Silicon Valley and
Washington, D.C. The firm represents half of the Fortune 100 and in a
Corporate Counsel survey in September 2007 was among the top firms
representing Fortune 250 companies. For additional information, visit
www.kslaw.com.